Literature DB >> 8499650

Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome.

S Kojima, K Kato, T Matsuyama, T Yoshikawa, K Horibe.   

Abstract

Entities:  

Mesh：

Year:  1993        PMID： 8499650

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Malignancies in Down syndrome.

Authors:  P Kusumakumary; T S Vats; R Ankathil; H R Gattamaneni; M K Nair
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

Review 2.  Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Authors:  J Timothy Caldwell; Yubin Ge; Jeffrey W Taub
Journal:  Expert Rev Hematol       Date:  2014-09-18       Impact factor: 2.929

3.  Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.

Authors:  S Yamada; T Hongo; S Okada; C Watanabe; Y Fujii; H Hori; M Yazaki; R Hanada; Y Horikoshi
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

4.  Improved outcome of acute myeloid leukaemia in Down's syndrome.

Authors:  J L Craze; G Harrison; K Wheatley; I M Hann; J M Chessells
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

5.  High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.

Authors:  Johann Hitzler; Todd Alonzo; Robert Gerbing; Amy Beckman; Betsy Hirsch; Susana Raimondi; Karen Chisholm; Shelton Viola; Lisa Brodersen; Michael Loken; Spencer Tong; Todd Druley; Maureen O'Brien; Nobuko Hijiya; Amy Heerema-McKenney; Yi-Chang Wang; Reuven Schore; Jeffrey Taub; Alan Gamis; E Anders Kolb; Jason N Berman
Journal:  Blood       Date:  2021-12-09       Impact factor: 22.113
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.